Advertisement MacroGenics, Takeda partner to develop four additional dart therapeutics - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

MacroGenics, Takeda partner to develop four additional dart therapeutics

US-based biopharmaceutical firm MacroGenics and Japan-based Takeda Pharmaceutical have entered into a collaboration agreement to develop and commercialize up to four product candidates.

In May 2014, the companies have agreed on the development of MGD010, and the four new research programs are in addition to that product.

Each of the four product candidates will be directed against jointly selected pairs of molecular targets and include the company’s Dual-Affinity Re-Targeting (DART) proprietary platform.

As part of the second deal, Takeda secures an option to obtain an exclusive worldwide license for each of the four product candidates and will be responsible for funding all research and development activities related to the programs, including reimbursement of MacroGenics’ expenses.

The deal will see MacroGenics receive up to an additional $400m in program initiation, pre-clinical, clinical, regulatory and commercialization milestone payments for each of four potential product candidates.

Following commercialization of these products, MacroGenics will be receiving double-digit royalties on any global net sales and has the option to co-promote each product candidate with Takeda in the US.

MacroGenics president and CEO Scott Koenig said the company is happy to enter its sixth DART collaboration with a major pharmaceutical company that has proven global development and commercialization capabilities.

"Building upon MGD010, I am very excited about the opportunity to expand our collaboration in the autoimmune area with an existing partner that has demonstrated clear support in enabling us to further broaden and accelerate our pipeline of innovative DART-based product candidates," Koenig said.